Significant Regulatory Milestone Towards Phase 2 in Recurrent GBM
FOR IMMEDIATE RELEASE Covington, KY ~ 30 July 2019 Bexion Pharmaceuticals, Inc. an oncology-focused company today announced the completion of a Type B End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) to [...]
KY Innovation, the state’s entrepreneurship and innovation enterprise, recently launched a new website
KY Innovation, the state’s entrepreneurship and innovation enterprise, recently launched a new website. Bexion is honored to be chosen as the model business at the intersection of innovation and public good. Please click on the [...]
Robert G. Savage Added to Bexion’s Board of Directors
FOR IMMEDIATE RELEASE Covington, KY ~ 23 May 2019 Bexion Pharmaceuticals, Inc. (Bexion) announced today that the company has added Bob Savage, MBA to its Board of Directors. Robert G. Savage Mr. Savage brings to [...]
Bexion Pharmaceuticals is developing innovative cures for cancer.
Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.
Clinical Trials
In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).
Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857